Real Options Analysis for Biotech R&D Decisions
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Decision questions
What this solution is built to answer.
Should the company invest now, wait for more evidence, expand, narrow, or abandon?
How much value comes from future managerial flexibility rather than the static plan?
Which assets need real-options analysis and which should stay in standard risk-adjusted valuation?
How does volatility, time to decision, and investment cost change the action threshold?
Capabilities
What ARiDA can run for this use case.
Real-options fit check by development stage: preclinical through Phase II as critical, Phase III as selective, approved assets usually skipped.
Binomial and trinomial lattices for stage-gated managerial decisions.
Longstaff-Schwartz Monte Carlo for American-style option decisions.
Compound option modeling for multi-stage development chains.
Exercise boundary, volatility surface, Greeks, time decay, and method-comparison outputs.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| valuation-enterprise-workflow | Runs the real-options analysis suite per applicable asset | VALUATION__ROA, decision tree, lattice, boundary, volatility, decomposition |
| portfolio-optimization | Connects optionality to capital allocation | Efficient frontier, scenario stress, resource allocation, board dossier |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Real-options fit matrix across assets.
WAIT vs EXERCISE decision maps.
Option value decomposition from static NPV to total strategic value.
Method-comparison table across binomial, Monte Carlo, and related methods.
Proof points
The enterprise valuation workflow skips real-options analysis for assets with little meaningful R&D flexibility.
Real-options analysis sits alongside baseline valuation so the underlying value case remains auditable.
Outputs are file artifacts with decision maps, boundaries, and decomposition tables.
FAQ
Common evaluation questions.
When is ROA appropriate in biotech?
Real-options analysis is most useful when future decisions can change the path of the asset: defer, expand, abandon, stage, switch indications, or preserve optionality while uncertainty resolves.
Does real-options analysis replace rNPV?
ARiDA treats risk-adjusted NPV as the baseline and real-options analysis as the layer that quantifies decision flexibility around that baseline.
Related solutions
Biotech Valuation
ARiDA runs evidence-backed biotech valuation workflows across single assets, multi-asset portfolios, platforms, fundraises, real options, Monte Carlo risk, and board dossiers.
Portfolio Optimization
Prioritize and defend a biopharma portfolio with value modeling, correlation, downside risk, stage-gate logic, scenarios, and board-ready recommendations.
Clinical Trial Intelligence
Analyze trial landscapes, protocol patterns, endpoints, enrollment signals, sponsor behavior, recent registry changes, and historical AACT structure.
Related reading
How to Produce an Investor-Grade Biotech Valuation Pack
An investor-grade valuation pack starts with an explicit argument about what must be true for the asset to be worth the number.
Why Board-Ready Outputs Require More Than Chat
Chat is a useful control layer, but board-ready biotech and pharma deliverables need production structure beneath the conversation.
Designing AI Research Systems for Biotech: Tools, Workflows, and Durable State
Biotech research systems need workflow structure, specialist lanes, files, and repeatable execution paths around the model.